Related Experiment Video
Updated: Aug 20, 2026
Exploring Independent Effects of Follicle-Stimulating Hormone In Vivo in a Mouse Model
Published on: August 11, 2023
Effect of urinary versus recombinant follicle-stimulating hormone on platelet function and other hemostatic variables
Jacob Bar1, Raoul Orvieto, Judith Lahav
1Perinatal Division, Infertility and IVF Unit, Department of Obstetrics and Gynecology, and Hemostatic Laboratory, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel. jbar@clalit.org.il
Objective:
To determine the effect of urinary versus recombinant FSH on platelet function and hemostatic variables in women undergoing controlled ovarian hyperstimulation cycles.
Design:
Randomized clinical study.
Setting:
Major university-based infertility and in vitro fertilization unit and hemostasis laboratory.
Patient(S):
Ten healthy women (in vitro study), and 24 women undergoing routine controlled ovarian hyperstimulation cycles (in vivo study), randomly assigned to receive either urinary (u-FSH) or recombinant gonadotropin (r-FSH).
Intervention(S):
In vitro study: effect of preincubation of plasma with u-FSH or r-FSH, in the presence or absence of estradiol, on platelet function and coagulation parameters. In vivo study: Changes in platelet function and coagulation parameters after treatment with u-FSH or r-FSH during controlled ovarian hyperstimulation cycles.
Main Outcome Measure(S):
Platelet aggregation and ATP release, activated protein C resistance ratio, free protein S.
Result(S):
In vitro study: Platelet aggregation and ATP release were significantly inhibited by u-FSH relative to r-FSH in both the presence and absence of estradiol (P=.047). In vivo study: Platelet function was significantly inhibited after treatment with u-FSH (P=.05) but not with r-FSH. In both studies, small changes of minor clinical significance were noted in activated protein C resistance and free protein S levels.
Conclusion(S):
The different platelet response to u-FSH and r-FSH may have clinical implications in selected patients, especially those at risk of thromboembolic complications, in decisions regarding the appropriate medication for controlled ovarian hyperstimulation cycles.
